Immunoglobulin Or Antibody Is Chimeric, Mutated, Or A Recombined Hybrid (e.g., Bifunctional, Bispecific, Rodent-human Chimeric, Single Chain, Rfv, Immunoglobuin Fusion Protein, Etc.) Patents (Class 435/328)
-
Publication number: 20130266517Abstract: The present application discloses humanized 1H7 antibodies. The antibodies bind to human alpha synuclein and can be used for treatment and diagnosis of Lewy body disease.Type: ApplicationFiled: January 25, 2013Publication date: October 10, 2013Inventors: Jose Saldanha, Tarlochan S. Nijjar
-
Publication number: 20130266558Abstract: Provided herein are chimeric and humanized versions of anti-CD22 mouse monoclonal antibody, HB22.7, which comprise human or humanized framework regions of the immunoglobulin heavy chain variable region (“VH”) and light chain variable region (“VK”). The FW regions may contain one or more backmutations in which a human FW residue is exchanged for the corresponding residue present in the parental mouse heavy or light chain. The human or humanized VH framework regions may comprise one or more of the following residues: a valine at position 24 of FW1, a glycine at position 49 of FW2, and an asparagine at position 73 of FW3, numbered according to Kabat. Further provided are pharmaceutical and immunotherapeutic compositions, and methods using anti-CD22 antibodies that preferably mediate human ADCC, CDC, and/or apoptosis for: the treatment of B cell diseases in humans, including B cell malignancies, autoimmune disease, GVHD, humoral rejection, and post-transplantation lymphoproliferative disorder.Type: ApplicationFiled: February 28, 2013Publication date: October 10, 2013Inventors: Tarran Jones, David G. Williams
-
Publication number: 20130266565Abstract: The invention provides a fusion protein comprising an antibody that binds to a human major histocompatibility complex presenting a peptidic fragment of a hepatitis-B-virus protein and an anti-viral cytokine and methods of using the same.Type: ApplicationFiled: February 4, 2013Publication date: October 10, 2013Inventors: Stefan Jenewein, Erhard Kopetzki, Stefan Ries, Georg Tiefenthaler
-
Publication number: 20130263293Abstract: The invention discloses methods for the generation of chimaeric human—non-human antibodies and chimaeric antibody chains, antibodies and antibody chains so produced, and derivatives thereof including fully humanised antibodies; compositions comprising said antibodies, antibody chains and derivatives, as well as cells, non-human mammals and vectors, suitable for use in said methods.Type: ApplicationFiled: March 28, 2012Publication date: October 3, 2013Applicant: Kymab LimitedInventors: Allan Bradley, E-Chiang Lee, Qi Liang, Wei Wang, Dominik Spensberger, Hui Liu, Jasper Clube
-
Publication number: 20130259806Abstract: The invention relates generally to dimeric molecular complexes comprising two fusion proteins. Each fusion protein comprises a biological effector moiety, a polypeptide spacer sequence, and an IgE CH4 dimerization domain. The dimeric molecular complexes may be conjugated, at a defined site, to other molecules including drug moieties, cytotoxic agents, labels (such as detectable labels), or biocompatible polymers.Type: ApplicationFiled: December 7, 2011Publication date: October 3, 2013Inventors: David Light, Paul Szymanski, Marian Seto, Aline Cornelius
-
Publication number: 20130261115Abstract: The invention relates to substituted imidazo-, pyrazolopyrazines and imidazotriazines and processes for their preparation, and their use for the manufacture of medicaments for the treatment and/or prophylaxis of diseases, in particular of hematological disorders, preferably of leukopenias and neutropenias.Type: ApplicationFiled: May 30, 2013Publication date: October 3, 2013Inventors: Stephan SIEGEL, Andreas WILMEN, Susanne RÖHRIG, Niels SVENSTRUP, Mark Jean GNOTH, Stefan HEITMEIER, Ulrich RESTER, Adrian TERSTEEGEN, Michael GERISCH
-
Publication number: 20130259881Abstract: A fusion polypeptide comprising (A)x-M-(A?)y, wherein A and A? are each polypeptides capable of binding a target receptor. The fusion polypeptides of the invention form multimeric proteins which activate the target receptor. A and A? may be each be an antibody or fragment derived from an antibody specific for a target receptor, such as the same or different scFv fragments, and/or a ligand or ligand fragment or derivative capable of binding the target protein, M is a multimerizing component, and X and Y are independently a number between 1-10.Type: ApplicationFiled: May 13, 2013Publication date: October 3, 2013Applicant: Regeneron Pharmaceuticals, Inc.Inventors: James P. Fandl, Gang Chen, Nicholas J. Papadopoulos, Thomas H. Aldrich
-
Publication number: 20130259859Abstract: Ang2-binding molecules, preferably Ang2-binding immunoglobulin single variable domains like VHHs and domain antibodies, pharmaceutical compositions containing same and their use in the treatment of diseases that are associated with Ang2-mediated effects on angiogenesis. Nucleic acids encoding Ang2-binding molecules, host cells and methods for preparing same.Type: ApplicationFiled: March 28, 2013Publication date: October 3, 2013Applicant: BOEHRINGER INGELHEIM INTERNATIONAL GMBHInventors: Rene Georg OTT, Eric BORGES, Andreas GSCHWIND, Joachim BOUCNEAU, Marie-Ange BUYSE, Erik DEPLA, Pascal MERCHIERS, Frederik STEVENAERT
-
Publication number: 20130263292Abstract: The invention discloses methods for the generation of chimaeric human-non-human antibodies and chimaeric antibody chains, antibodies and antibody chains so produced, and derivatives thereof including fully humanised antibodies; compositions comprising said antibodies, antibody chains and derivatives, as well as cells, non-human mammals and vectors, suitable for use in said methods.Type: ApplicationFiled: March 29, 2012Publication date: October 3, 2013Applicant: Kymab LimitedInventors: Qi Liang, Allan Bradley, E-Chiang Lee, Wei Wang, Dominik Spensberger, Hui Liu, Jasper Clube
-
Publication number: 20130259861Abstract: This invention relates to methods of treating disease with soluble inhibitors of the lymphotoxin pathway having improved properties. This invention also relates to improved LTBR-Ig fusion proteins, and pharmaceutical compositions thereof.Type: ApplicationFiled: November 20, 2012Publication date: October 3, 2013Applicant: BIOGEN IDEC MA INC.Inventors: Evan BECKMAN, Graham K. FARRINGTON, Werner MEIER, Jeffrey L. BROWNING
-
Patent number: 8545844Abstract: The invention relates to humanized antibodies against human IL-22RA and to their use in the treatment of psoriasis and other immune-mediated diseases such as psoriatic arthritis and atopic dermatitis.Type: GrantFiled: November 12, 2010Date of Patent: October 1, 2013Assignee: Merck Serona SAInventors: Roland Beckmann, Caroline Johnson-Leger
-
Publication number: 20130251717Abstract: The present invention relates to novel humanized anti-IL-4 and IL-13 antibodies and fragments thereof and novel bispecific antibodies and fragments thereof that specifically bind to IL-4 and IL-13. The invention also includes uses of the antibodies to treat or prevent IL-4 and/or IL-13 mediated diseases or disorders, including allergic asthma and dermatitis.Type: ApplicationFiled: March 11, 2013Publication date: September 26, 2013Applicant: SANOFIInventors: Ercole RAO, Vincent MIKOL, Danxi LI, Jochen KRUIP, Matthew DAVISON
-
Publication number: 20130251716Abstract: The present invention relates to novel humanized anti-IL-4 and IL-13 antibodies and fragments thereof and novel bispecific antibodies and fragments thereof that specifically bind to IL-4 and IL-13. The invention also includes uses of the antibodies to treat or prevent IL-4 and/or IL-13 mediated diseases or disorders, including allergic asthma and dermatitis.Type: ApplicationFiled: March 11, 2013Publication date: September 26, 2013Applicant: SanofiInventors: Ercole RAO, Vincent MIKOL, Danxi LI, Jochen KRUIP, Matthew DAVISON
-
Patent number: 8541203Abstract: Activatable binding polypeptides (ABPs), which contain a target binding moiety (TBM), a masking moiety (MM), and a cleavable moiety (CM) are provided. Activatable antibody compositions, which contain a TBM containing an antigen binding domain (ABD), a MM and a CM are provided. Furthermore, ABPs which contain a first TBM, a second TBM and a CM are provided. The ABPs exhibit an “activatable” conformation such that at least one of the TBMs is less accessible to target when uncleaved than after cleavage of the CM in the presence of a cleaving agent capable of cleaving the CM. Further provided are libraries of candidate ABPs, methods of screening to identify such ABPs, and methods of use. Further provided are ABPs having TBMs that bind VEGF, CTLA-4, or VCAM, ABPs having a first TBM that binds VEGF and a second TBM that binds FGF, as well as compositions and methods of use.Type: GrantFiled: March 2, 2012Date of Patent: September 24, 2013Assignees: The Regents of the University of California, CytomX Therapeutics, Inc.Inventors: Patrick Sean Daugherty, Nancy Stagliano, Jerry Thomas, James W. West, Jason Sagert
-
Publication number: 20130243759Abstract: The present invention relates inter alia to fertile non-human vertebrates such as mice and rats useful for producing antibodies bearing human variable regions, in which endogenous antibody chain expression has been inactivated.Type: ApplicationFiled: March 15, 2013Publication date: September 19, 2013Applicant: KYMAB LTD.Inventors: Glenn A. Friedrich, E-Chiang Lee
-
Publication number: 20130243777Abstract: The present invention relates to novel humanized anti-IL-4 and IL-13 antibodies and fragments thereof and novel bispecific antibodies and fragments thereof that specifically bind to IL-4 and IL-13. The invention also includes uses of the antibodies to treat or prevent IL-4 and/or IL-13 mediated diseases or disorders, including allergic asthma and dermatitis.Type: ApplicationFiled: March 15, 2013Publication date: September 19, 2013Applicant: SanofiInventors: Ercole RAO, Vincent MIKOL, Danxi LI, Jochen KRUIP, Matthew DAVISON
-
Publication number: 20130243772Abstract: The invention relates to antibody molecules having specificity for antigenic determinants of human OX40, therapeutic uses of the antibody molecules and methods for producing said antibody molecules.Type: ApplicationFiled: November 8, 2012Publication date: September 19, 2013Applicant: UCB Pharma S.A.Inventors: Ralph Adams, Pallavi Bhatta, Sam Phillip Heywood, David Paul Humphreys
-
Publication number: 20130243760Abstract: The present invention provides and includes monoclonal antibodies (mAbs) preferentially selective for HER2 antigens, hybridoma lines that secrete these HER2 antibodies or antibody fragments, and the use of such antibodies and antibody fragments to detect HER2 antigens, particularly those expressed by cancer cells. The present invention also includes antibodies that are specific for or show preferential binding to a soluble or secreted form of HER2. The present invention also includes an antibody or antibody fragment that is capable of reducing the activity of HER2 in at least one form, including a soluble form or a secreted form. The present invention further includes chimeric antibodies, processes for producing monoclonal and chimeric antibodies or monoclonal or chimeric antibodies, and their therapeutic uses, particularly in the detection of cancer most preferentially in human breast, stomach, and colon.Type: ApplicationFiled: May 1, 2013Publication date: September 19, 2013Applicant: Alper BioTech, LLCInventor: Özge Alper
-
Publication number: 20130244324Abstract: In certain aspects, the present invention provides compositions and methods for increasing red blood cell and/or hemoglobin levels in vertebrates, including rodents and primates, and particularly in humans.Type: ApplicationFiled: January 25, 2013Publication date: September 19, 2013Applicant: ACCELERON PHARMA, INC.Inventors: Jasbir Seehra, Robert Scott Pearsall, Ravindra Kumar
-
Publication number: 20130243776Abstract: The present invention relates to novel humanized anti-IL-4 and IL-13 antibodies and fragments thereof and novel bispecific antibodies and fragments thereof that specifically bind to IL-4 and IL-13. The invention also includes uses of the antibodies to treat or prevent IL-4 and/or IL-13 mediated diseases or disorders, including allergic asthma and dermatitis.Type: ApplicationFiled: March 15, 2013Publication date: September 19, 2013Applicant: SanofiInventors: Ercole RAO, Vincent MIKOL, Danxi LI, Jochen KRUIP, Matthew DAVISON
-
Publication number: 20130243778Abstract: The present invention relates to novel humanized anti-IL-4 and IL-13 antibodies and fragments thereof and novel bispecific antibodies and fragments thereof that specifically bind to IL-4 and IL-13. The invention also includes uses of the antibodies to treat or prevent IL-4 and/or IL-13 mediated diseases or disorders, including allergic asthma and dermatitis.Type: ApplicationFiled: March 15, 2013Publication date: September 19, 2013Applicant: SanofiInventors: Ercole RAO, Vincent MIKOL, Danxi LI, Jochen KRUIP, Matthew DAVISON
-
Publication number: 20130236902Abstract: The present disclosure enables collections of variable heavy chain and variable light chain pairs comprising, in part, germline protein sequences that are pre-selected for functional properties relevant to developability, wherein the collections may be used to select against any antigen using, for example, phage display.Type: ApplicationFiled: November 18, 2011Publication date: September 12, 2013Applicant: MorphoSys AGInventors: Stefanie Urlinger, Thomas Tiller, Ingrid Schuster, Yvonne Stark
-
Publication number: 20130236462Abstract: The present invention relates to novel humanized anti-IL-4 and IL-13 antibodies and fragments thereof and novel bispecific antibodies and fragments thereof that specifically bind to IL-4 and IL-13. The invention also includes uses of the antibodies to treat or prevent IL-4 and/or IL-13 mediated diseases or disorders, including allergic asthma and dermatitis.Type: ApplicationFiled: March 11, 2013Publication date: September 12, 2013Applicant: SANOFIInventors: Ercole RAO, Vincent MIKOL, Danxi LI, Jochen KRUIP, Matthew DAVISON
-
Publication number: 20130236461Abstract: The present invention relates to novel humanized anti-IL-4 and IL-13 antibodies and fragments thereof and novel bispecific antibodies and fragments thereof that specifically bind to IL-4 and IL-13. The invention also includes uses of the antibodies to treat or prevent IL-4 and/or IL-13 mediated diseases or disorders, including allergic asthma and dermatitis.Type: ApplicationFiled: March 11, 2013Publication date: September 12, 2013Applicant: SANOFIInventors: Ercole RAO, Vincent MIKOL, Danxi LI, Jochen KRUIP, Matthew DAVISON
-
Publication number: 20130236460Abstract: The present invention relates to novel humanized anti-IL-4 and IL-13 antibodies and fragments thereof and novel bispecific antibodies and fragments thereof that specifically bind to IL-4 and IL-13. The invention also includes uses of the antibodies to treat or prevent IL-4 and/or IL-13 mediated diseases or disorders, including allergic asthma and dermatitis.Type: ApplicationFiled: March 11, 2013Publication date: September 12, 2013Applicant: SANOFIInventors: Ercole RAO, Vincent MIKOL, Danxi LI, Jochen KRUIP, Matthew DAVISON
-
Publication number: 20130236458Abstract: Engineered multivalent and multispecific binding proteins that bind IL-13 and/or IL-17 are provided, along with methods of making and uses in the prevention, diagnosis, and/or treatment of disease.Type: ApplicationFiled: December 28, 2012Publication date: September 12, 2013Applicant: AbbVie Inc.Inventors: Chung-Ming HSIEH, Tariq Ghayur, Carrie L. Goodreau
-
Patent number: 8529899Abstract: Disclosed are fusion proteins comprising a biologically active molecule and an immunoglobulin (Ig) Fc domain which is linked to the biologically active molecule. The Fc domain is a hybrid human Fc domain of (i) IgG1, IgG2 or IgG4 or (ii) IgG4 and IgD. The hybrid Fc is useful as a carrier of biologically active molecules.Type: GrantFiled: June 11, 2012Date of Patent: September 10, 2013Assignees: Genexine, Inc., Postech Academy-Industry FoundationInventors: Sehwan Yang, Young Chul Sung
-
Patent number: 8529902Abstract: Isolated human monoclonal antibodies which bind to and inhibit human CD20, and related antibody-based compositions and molecules, are disclosed. The human antibodies can be produced by a transfectoma or in a non-human transgenic animal, e.g., a transgenic mouse, capable of producing multiple isotypes of human monoclonal antibodies by undergoing V-D-J recombination and isotype switching. Also disclosed are pharmaceutical compositions comprising the human antibodies, non-human transgenic animals and hybridomas which produce the human antibodies, and therapeutic and diagnostic methods for using the human antibodies.Type: GrantFiled: October 17, 2003Date of Patent: September 10, 2013Assignee: Genmab A/SInventors: Jessica Teeling, Sigrid Ruuls, Martin Glennie, Jan G. J. van de Winkel, Paul Parren, Jørgen Petersen, Ole Baadsgaard, Haichun Huang
-
Publication number: 20130230525Abstract: Provided herein in certain embodiments are polypeptide complexes capable of binding to an antigen. Pharmaceutical compositions, method of using the polypeptide complexes are also provided.Type: ApplicationFiled: November 9, 2011Publication date: September 5, 2013Applicant: ALTIMAB THERAPEUTICS, INC.Inventors: Zijuan Li, Chun Wu, Jun Bao, Bo Chen
-
Publication number: 20130230519Abstract: The invention relates to improved variants of the anti-serum albumin immunoglobulin single variable domain DOM7h-14-10, as well as ligands and drug conjugates comprising such variants, compositions, nucleic acids, vectors and hosts.Type: ApplicationFiled: August 12, 2011Publication date: September 5, 2013Inventors: Elena De Angelis, Carolyn Enever, Haiqun Liu, Malgorzata Pupecka-Swider, Oliver Schon
-
Publication number: 20130224191Abstract: Novel modulators, including antibodies and derivatives thereof, and methods of using such modulators to treat hyperproliferative disorders are provided.Type: ApplicationFiled: August 26, 2011Publication date: August 29, 2013Inventors: Robert A. Stull, Scott J. Dylla, Orit Foord, Monette Aujay
-
Publication number: 20130224190Abstract: The present invention relates to an anti-CD19 antibody having a variant Fc region having some specific amino acid modifications relative to a wild-type Fc region which confer one or several useful effector functions. The present invention relates in particular to chimeric, humanized or full human anti-CD19 antibodies comprising such a variant Fc region. It relates advantageously to antibodies with an interesting and valuable glycosylation profile, especially a low fucose level and/or a high oligomannose level and low level of sialylated glycoform. The present invention also relates to the use of these antibodies in the treatment, prevention or management of disease or disorder, such as cancer, especially a B-cell malignancy, and auto-immune disease.Type: ApplicationFiled: July 18, 2011Publication date: August 29, 2013Applicant: INTERNATIONAL - DRUG - DEVELOPMENT - BIOTECHInventors: Claudine Vermot-Desroches, Boris Sebastien Vuillermoz
-
Publication number: 20130224196Abstract: The present invention is directed to methods, kits and compositions for preventing or treating age-related conditions or metabolic disorders. The Klotho fusion polypeptides of the invention include at least a Klotho protein or an active fragment thereof. In one embodiment, the fusion polypeptide comprises a Klotho polypeptide, a FGF (such as FGF23) and (optionally) a modified Fc fragment. The Fc fragment can, for example, have decreased binding to Fc-gamma-receptor and increased serum half-life. The Klotho fusion proteins are useful in the treatment and prevention of a variety of age-related conditions and metabolic disorders. In another embodiment, the fusion polypeptide comprises a FGF (such as FGF23) and a modified Fc fragment.Type: ApplicationFiled: March 12, 2013Publication date: August 29, 2013Inventors: David GLASS, Shou-Ih HU
-
Publication number: 20130224205Abstract: The present invention provides a cytotoxically active CD3 specific binding construct comprising a first domain specifically binding to human CD3 and an Ig-derived second binding domain. Furthermore, a nucleic acid sequence encoding a CD3 specific binding construct of the invention is provided. Further aspects of the invention are vectors and host cells comprising said nucleic acid sequence, a process for the production of the construct of the invention and composition comprising said construct. The invention also provides the use of said constructs for the preparation of pharmaceutical compositions for the treatment of particular diseases, a method for the treatment of particular diseases and a kit comprising the binding construct of the invention.Type: ApplicationFiled: December 12, 2011Publication date: August 29, 2013Inventors: Robert HOFMEISTER, Birgit Kohleisen, Ulla Lenkkeri-Schütz, Christian Itin, Patrick Bäuerle, Francis J. Carr, Anita A. Hamilton, Stephen Williams
-
Publication number: 20130224202Abstract: Disclosed herein are a monoclonal antibody that specifically binds to human CD 133 and single-chain variable fragments thereof. Also disclosed herein is a hybridoma that produces the monoclonal antibody that specifically binds to human CD133.Type: ApplicationFiled: December 10, 2010Publication date: August 29, 2013Applicant: REGENTS OF THE UNIVERSITY OF MINNESOTAInventor: Karen Himmel Ohlfest
-
Publication number: 20130224198Abstract: A recombinant fusion protein comprising a human erythropoietin peptide portion linked to an immunoglobulin peptide portion is described. The fusion protein has a prolonged half-life in vivo compared to naturally occurring or recombinant native human erythropoietin. In one embodiment, the protein has a half-life in vivo at least three-fold higher than native human erythropoietin. The fusion protein exhibits enhanced erythropoietic bioactivity compared to native human erythropoietin. In one embodiment, the fusion protein comprises the complete peptide sequence of a human erythropoietin (EPO) molecule and the peptide sequence of an Fc fragment of human IgG1, which Fc fragment includes the hinge region, CH2 and CH3 domains. The EPO molecule may be linked directly to the Fc fragment to avoid extraneous peptide linkers and lessen risk of an immunogenic response when administered. In one embodiment the hinge region is a human Fc fragment variant having a non-cysteine residue at amino acid 6.Type: ApplicationFiled: April 29, 2013Publication date: August 29, 2013Applicant: NOVAGEN HOLDING CORPORATIONInventors: Haitao WANG, Yong DU, Rui ZHANG, Jing XU, Longbin LIU
-
Publication number: 20130225668Abstract: The invention provides chimeric antigen receptors (CARs) comprising an antigen binding domain of a KDR-1121 or DC101 antibody, an extracellular hinge domain, a T cell receptor transmembrane domain, and an intracellular domain T cell receptor signaling domain. Nucleic acids, recombinant expression vectors, host cells, populations of cells, antibodies, or antigen binding portions thereof, and pharmaceutical compositions relating to the CARs are disclosed. Methods of detecting the presence of cancer in a host and methods of treating or preventing cancer in a host are also disclosed.Type: ApplicationFiled: May 2, 2013Publication date: August 29, 2013Applicant: The United States of America, as represented by the Secretary, Department of Health and HumanInventor: The United States of America, as represented by the Secretary, Department of Health and Human Services
-
Publication number: 20130216528Abstract: In this application are described chimeric, humanized, affinity matured, stability enhanced, and bispecific Anti-GD2 antibodies and fragments thereof. Also provided are methods of using individual antibodies or compositions thereof for the detection, prevention, and/or therapeutical treatment of GD2-related diseases, in particular, neuroblastoma.Type: ApplicationFiled: June 20, 2011Publication date: August 22, 2013Inventors: Nai-Kong Cheung, Mahiuddin Ahmed
-
Publication number: 20130216543Abstract: The present invention features antibody-based constructs that include a combination of two or more of a tetrameric antibody, a single chain antibody, a diabody, a triabody, another immunoglobulin-based moiety, as described herein, or biologically active variants thereof.Type: ApplicationFiled: August 20, 2011Publication date: August 22, 2013Applicant: MASSACHUSETTS INSTITUTE OF TECHNOLOGYInventors: Karl Dane Wittrup, Jamie B. Spangler, Benjamin E. Epstein, Brian L. Ross
-
Publication number: 20130216544Abstract: The invention relates to antibodies against the human La protein and to their use in immunotargeting, in particular the immunotargeting of tumour cells. The object of the invention is to provide improved antibodies which bind universal target structures on the surface of tumour cells, and to provide novel anti-La antibodies, in particular with a high affinity for La, a universal target structure on tumour cells, which make it possible to use the antibodies as recombinant fragments for immunotargeting. The invention comprises recombinant antibodies comprising: i. a binding unit of an antibody which specifically binds to an epitope of a human nuclear antigen, preferably human La protein, and ii. a binding unit of an antibody which specifically binds to an effector cell or of a ligand which specifically binds to an effector cell. The invention furthermore comprises novel antibodies which specifically bind the human La protein.Type: ApplicationFiled: August 5, 2011Publication date: August 22, 2013Applicant: TECHNISCHE UNIVERSITAET DRESDENInventor: Michael Bachmann
-
Publication number: 20130216539Abstract: The present invention includes methods of generating derivatives of a protein, as well as methods of treating a subject with the derivatized proteins. More particularly, the present invention includes methods of generating derivatives of HSP 70 proteins and methods of treating a subject with the derivatized HSP 70 proteins.Type: ApplicationFiled: February 15, 2013Publication date: August 22, 2013Applicant: ALS Biopharma, LLCInventor: ALS Biopharma, LLC
-
Patent number: 8513199Abstract: Antigen binding proteins that bind to human c-fms protein are provided. Nucleic acids encoding the antigen binding protein, vectors, and cells encoding the same are also provided. The antigen binding proteins can inhibit binding of c-fms to CSF-1, reduce monocyte migration into tumors, and reduce the accumulation of tumor-associated macrophages.Type: GrantFiled: May 8, 2012Date of Patent: August 20, 2013Assignee: Amgen Inc.Inventors: Kenneth Allan Brasel, James F Smothers, Douglas Pat Cerretti
-
Publication number: 20130209454Abstract: Embodiments of the present invention are directed to compositions and methods for anti-HIV (anti-CD4 binding site) antibodies having improved potency and breadth.Type: ApplicationFiled: December 13, 2012Publication date: August 15, 2013Applicants: THE ROCKEFELLER UNIVERSITY, CALIFORNIA INSTITUTE OF TECHNOLOGYInventors: CALIFORNIA INSTITUTE OF TECHNOLOGY, THE ROCKEFELLER UNIVERSITY
-
Publication number: 20130209469Abstract: The present invention relates to novel humanized anti-IL-4 and IL-13 antibodies and fragments thereof and novel bispecific antibodies and fragments thereof that specifically bind to IL-4 and IL-13. The invention also includes uses of the antibodies to treat or prevent IL-4 and/or IL-13 mediated diseases or disorders, including allergic asthma and dermatitis.Type: ApplicationFiled: February 4, 2013Publication date: August 15, 2013Applicant: SANOFIInventors: Ercole RAO, Vincent MIKOL, Danxi LI, Jochen KRUIP, Matthew DAVISON
-
Publication number: 20130209457Abstract: The present invention relates to a variant Fc region comprising an amino acid substitution at position 238 of the Fc region as compared to a human parent Fc region, wherein the variant Fc region comprises a 238D substitution, wherein the variant Fc region binds Fc?RIIb with increased binding affinity compared to a human parent Fc region.Type: ApplicationFiled: February 11, 2013Publication date: August 15, 2013Applicant: Xencor, Inc.Inventors: Gregory Alan Lazar, Wei Dang, John Desjarlais, Sher Bahadur Karki, Omid Vafa, Robert Hayes, Jost Vielmetter
-
Publication number: 20130212719Abstract: Non-human animals, tissues, cells, and genetic material are provided that comprise a modification of an endogenous non-human heavy chain immunoglobulin sequence and that comprise an ADAM6 activity functional in a rodent (e.g., a mouse), wherein the non-human animals rearrange human immunoglobulin light chain gene segments in the context of heavy chain constant regions and express immunoglobulin-like molecules comprising human immunoglobulin light chain variable domains fused to heavy chain constant domains that are cognate with human immunoglobulin light chain variable domains fused to light chain constant domains.Type: ApplicationFiled: February 1, 2013Publication date: August 15, 2013Applicant: Regeneron Pharmaceuticals, Inc.Inventor: Regeneron Pharmaceuticals, Inc.
-
Publication number: 20130209455Abstract: The present invention relates to humanized antibodies against human CDCP1 (anti-CDCP1 antibody), methods for their production, pharmaceutical compositions containing said antibodies, and uses thereof.Type: ApplicationFiled: December 20, 2012Publication date: August 15, 2013Applicant: Roche Glycart AGInventor: Roche Glycart AG
-
Publication number: 20130210137Abstract: A method for engineering and utilizing large DNA vectors to target, via homologous recombination, and modify, in any desirable fashion, endogenous genes and chromosomal loci in eukaryotic cells. These large DNA targeting vectors for eukaryotic cells, termed LTVECs, are derived from fragments of cloned genomic DNA larger than those typically used by other approaches intended to perform homologous targeting in eukaryotic cells. Also provided is a rapid and convenient method of detecting eukaryotic cells in which the LTVEC has correctly targeted and modified the desired endogenous gene(s) or chromosomal locus (loci) as well as the use of these cells to generate organisms bearing the genetic modification.Type: ApplicationFiled: December 19, 2012Publication date: August 15, 2013Applicant: Regeneron Pharmaceuticals, Inc.Inventor: Regeneron Pharmaceuticals, Inc.
-
Publication number: 20130202569Abstract: The present invention provides ungulates, including pigs, expressing CTLA4-Ig, as well as tissue, organs, cells and cell lines derived from such animals. Such animals, tissues, organs and cells can be used in research and medical therapy, including xenotransplanation. In addition, methods are provided to prepare organs, tissues and cells expressing the CTLA4-Ig for use in xenotransplantation, and nucleic acid constructs and vectors useful therein.Type: ApplicationFiled: May 17, 2012Publication date: August 8, 2013Inventor: David Lee Ayares
-
Publication number: 20130202596Abstract: The present invention features inter alia nucleic acid molecules which encode polypeptides comprising a single chain Fc region and the polypeptides they encode. The Fc moieties of these constructs are linked by a cleavable scFc linker which is adjacent to at least one enzymatic cleavage site, e.g., an intracellular processing site. The resulting processed molecules comprise two polypeptide chains and substantially lack the extraneous amino acid sequence found in single chain Fc linker molecule. Methods of making and using these dimeric molecules are also described.Type: ApplicationFiled: July 11, 2011Publication date: August 8, 2013Applicant: BIOGEN IDEC HEMOPHILIA INC.Inventors: Joe Salas, Robert Peters